

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/899,186		07/06/2001	Shinji Nara	766.38	2692
5514	7590	05/26/2004		EXAMINER	
FITZPATR	ICK CEI	LLA HARPER & S	COVINGTON, RAYMOND K		
30 ROCKEI	FELLER P	PLAZA		<u></u>	
NEW YORI	NEW YORK, NY 10112			ART UNIT	PAPER NUMBER
			1625		

DATE MAILED: 05/26/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Cash +1	Application No.	Applicant(s)
Supplemental Notice of Allowability	09/899,186	NARA ET AL.
Notice of Allowability	Examiner	Art Unit
	Raymond Covington	1625
The MAILING DATE of this communication ap All claims being allowable, PROSECUTION ON THE MERITS herewith (or previously mailed), a Notice of Allowance (PTOL- NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT of the Office or upon petition by the applicant. See 37 CFR 1.3	IS (OR REMAINS) CLOSED in (85) or other appropriate commur RIGHTS. This application is su	this application. If not included nication will be mailed in due course. <b>THIS</b>
1. This communication is responsive to <u>10/10/03</u> .		
2. ⊠ The allowed claim(s) is/are <u>1-26</u> .		
3. The drawings filed on are accepted by the Exam	iner.	
<ul> <li>4. Acknowledgment is made of a claim for foreign priority a) All b) Some* c) None of the:</li> <li>1. Certified copies of the priority documents h</li> <li>2. Certified copies of the priority documents h</li> <li>3. Copies of the certified copies of the priority International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> </ul>	ave been received. ave been received in Application	No
Applicant has THREE MONTHS FROM THE "MAILING DAT noted below. Failure to timely comply will result in ABANDO THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		a reply complying with the requirements
<ol> <li>A SUBSTITUTE OATH OR DECLARATION must be su INFORMAL PATENT APPLICATION (PTO-152) which g</li> </ol>		
<ul> <li>6. CORRECTED DRAWINGS (as "replacement sheets") r <ul> <li>(a) including changes required by the Notice of Draftsp</li> <li>1) hereto or 2) to Paper No./Mail Date</li> <li>(b) including changes required by the attached Examin Paper No./Mail Date</li> <li>Identifying indicia such as the application number (see 37 CF each sheet. Replacement sheet(s) should be labeled as such</li> </ul> </li> <li>7. DEPOSIT OF and/or INFORMATION about the de attached Examiner's comment regarding REQUIREMENT</li> </ul>	person's Patent Drawing Review enderson's Patent Drawing Review ender's Amendment / Comment or in R 1.84(c)) should be written on the in the header according to 37 CFR eposit of BIOLOGICAL MATEI	n the Office action of e drawings in the front (not the back) of 1.121(d). RIAL must be submitted. Note the
Attachment(s)  1. ☐ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-94)  3. ☐ Information Disclosure Statements (PTO-1449 or PTO/S Paper No./Mail Date	8) 6. ☑ Interview Sur Paper No./M B/08), 7. ☑ Examiner's A sit 8. ☐ Examiner's S	lail Date <u>12</u>
of Biological Material	9.	

Application/Control Number: 09/899,186 Page 2

Art Unit: 1625

## **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Lawrence Perry on March 4, 2003.

The application has been amended and Claims 6 and 9 have been rewritten, as follows:

- 6. (Previously Presented) A method of treating a patient with colon and pancreatic cancer, which comprises administrating to said patient a pharmacologically effective amount of the piperidine derivative or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 4.
- 9. (Previously Presented) The method of treating a patient according to claim 6, wherein the colon and pancreatic cancer is a tumor.

Art Unit: 1625

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Raymond Covington whose telephone number is (703) 308-4704. The examiner can normally be reached on M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, J. McKane can be reached on (571) 272-0699. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pairdirect.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

**Raymond Covington** 

Examiner
Art Unit 1625
5 3 05